Initiates Coverage on AcelRx Pharmaceuticals (NASDAQ:ACRX)

Analysts at began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) in a research report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

ACRX has been the subject of a number of other reports. HC Wainwright cut AcelRx Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, March 11th.

Shares of AcelRx Pharmaceuticals stock opened at $0.20 on Wednesday. The business has a 50-day moving average of $0.23 and a 200 day moving average of $0.36. AcelRx Pharmaceuticals has a 12 month low of $0.16 and a 12 month high of $1.55. The stock has a market capitalization of $29.28 million, a price-to-earnings ratio of -0.74 and a beta of 0.71.

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) last announced its earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $0.50 million. During the same quarter last year, the business earned ($0.08) earnings per share. Equities research analysts anticipate that AcelRx Pharmaceuticals will post -0.22 EPS for the current year.

A number of hedge funds have recently bought and sold shares of ACRX. Cornerstone Capital Inc. acquired a new stake in AcelRx Pharmaceuticals in the 4th quarter valued at about $45,000. apricus wealth LLC acquired a new stake in AcelRx Pharmaceuticals in the 4th quarter valued at about $73,000. Finally, Values First Advisors Inc. acquired a new stake in shares of AcelRx Pharmaceuticals during the 4th quarter worth about $291,000. 23.12% of the stock is currently owned by institutional investors.

About AcelRx Pharmaceuticals (Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

Featured Stories

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with's FREE daily email newsletter.